Please use this identifier to cite or link to this item:
|Title:||INVESTIGATING THE ROLE OF NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 (NRF2) IN BREAST CANCER CELL-STATE DYNAMICS||Authors:||CHUA SHU XIAN SERENE||Keywords:||Nuclear Factor Erythroid 2-Related Factor 2, Nrf2, Breast Cancer, MCF10CA1h, Cell-State Dynamics, Tumour Cell Plasticity||Issue Date:||12-Feb-2018||Citation:||CHUA SHU XIAN SERENE (2018-02-12). INVESTIGATING THE ROLE OF NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 (NRF2) IN BREAST CANCER CELL-STATE DYNAMICS. ScholarBank@NUS Repository.||Abstract:||Tumour heterogeneity describes the existence of malignant cells exhibiting distinct functional states within a tumour. Accumulating evidence suggest that interconversions can occur between cellular states. Understanding the signals driving these transitions will be crucial for development of effective treatments against the disease. Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) is a transcription factor that functions as a master regulator of antioxidant and cytoprotective responses. Given its pivotal role in tumour progression, we hypothesised that Nrf2 may be involved in governing breast cancer cell-state dynamics. A protocol was developed for prolonged siRNA-mediated silencing of Nrf2 in MCF10CA1h. Perturbations in cell-state equilibrium were observed; siNrf2-transfected cells switched from a pre-dominantly CD24-/EpCAM-/low to a CD24+/EpCAMmed/high phenotype. Expression of a mixed epithelial (E) /mesenchymal (M) signature, concomitant with increased stem-like traits and enhanced migratory capacity resembled transition to an intermediate E/M state. Our preliminary findings indicate potential involvement of Nrf2 in maintaining cell-state equilibrium.||URI:||http://scholarbank.nus.edu.sg/handle/10635/143082|
|Appears in Collections:||Master's Theses (Open)|
Show full item record
Files in This Item:
|ChuaSXS.pdf||4.91 MB||Adobe PDF|
checked on Jul 10, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.